AB0700 GOLIMUMAB PERSISTENCE IN BIOLOGIC NAÏVE AND NON-NAÏVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF THE GO-PRACTICE STUDY

Autor: Florence Tubach, Jean Ouaniche, Bruno Fautrel, Philippe Bertin, Eric Lespessailles, Philippe Goupille, N Gouyette, Naoual Harid, René-Marc Flipo, Jean-Marie Fayette

Publikováno v: Abstracts accepted for Publication.

Background: Golimumab (GLM) was the latest anti-TNFα therapy to be indicated in the treatment of chronic inflammatory rheumatic diseases. The pivotal GO-AFTER study [1] and the ongoing observational GO-BEYOND study investigate GLM efficacy in rheuma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f057edb65411d168a8573a96740e9b41
https://doi.org/10.1136/annrheumdis-2019-eular.5981

Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'

Autor: M. Bagot, D. Lons Danic, Etienne Audureau, Michel Richard, N. Gouyette, F. Roux, Alain Cantagrel, E. Dernis, Denis Jullien, Pascal Claudepierre, Thierry Passeron, P. Hilliquin, Frédéric Lioté

Publikováno v: Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Wiley, 2018, 32 (11), pp.1950-1953. ⟨10.1111/jdv.14861⟩

BACKGROUND Dermatologists are recommended to ask psoriasis patients about musculoskeletal complaints to allow early detection and treatment of psoriatic arthritis (PsA). Screening tools have been developed to help identify patients warranting further

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9809cfcda7fc27533b3db96e3a72824c
https://hal.archives-ouvertes.fr/hal-03699562

FRI0699 Determinants of 12-months persistence in ankylosing spondylitis patients initiating subcutaneous tnf-alpha inhibitors

Autor: Florence Tubach, Bruno Fautrel, M-C Woronoff, Manon Belhassen, Christophe Hudry, N Gouyette, A Clément, E. Van Ganse

Publikováno v: Poster Presentations.

Background Biotherapies such as subcutaneous tumour necrosis factor-alpha inhibitors (SC-TNFis) have transformed the management of inflammatory joint diseases such as ankylosing spondylitis (AS). The assessment of SC- TNFis persistence and its determ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::425d951281f26cfac2449fc4b7be3d55
https://doi.org/10.1136/annrheumdis-2017-eular.5052

AB0701 The real-life use of golimumab in patients with immune-mediated rheumatic diseases: one year results of the go-practice study

Autor: N Gouyette, E Lespesailles, R.M. Flipo, Jean Ouaniche, Florence Tubach, Philippe Bertin, Philippe Goupille, Bruno Fautrel

Publikováno v: Abstracts Accepted for Publication.

Background The GO-PRACTICE study was initiated to describe the use of Golimumab (GLM), a human anti-TNFα monoclonal antibody, in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in French clinical p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b751050ea9f4aff2312126629f89f82
https://doi.org/10.1136/annrheumdis-2017-eular.4073

Efficacité et sécurité de l’infliximab princeps pour traiter des patients atteints de maladie de Takayasu dans la cadre de la RTU (Recommandation Temporaire d’Utilisation) en France

Autor: J.F. Kleinmann, J. Sibilia, N. Gouyette, R. Tajima, E. Sauleau, Laurent Arnaud

Publikováno v: La Revue de Médecine Interne. 38:A110

Introduction Le rapport benefice/risque du traitement par infliximab de la maladie de Takayasu refractaire est presume favorable en se basant sur des etudes retrospectives avec un nombre limite de patients, dans lesquelles l’infliximab a ete prescr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fdcf6490567be81d33b258c93d624aa6
https://doi.org/10.1016/j.revmed.2017.10.012